Clinical Trial Update: Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating asciminib as maintenance therapy after allo-HCT or CAR T to prevent relapse in adults with Philadelphia chromosome-positive acute lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING